Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Novartis ( (NVS) ).
Novartis reported strong financial performance for the year 2024, with a 12% increase in net sales and a 22% rise in core operating income, driven by the success of key products like Entresto and Cosentyx. The company achieved significant innovation milestones, including regulatory approvals and positive study results, positioning itself for continued growth in 2025 with an anticipated dividend increase. The spinoff of Sandoz marked a strategic shift to a ‘pure-play’ innovative medicines business, enhancing Novartis’s focus on high-value medicines and operational excellence, as well as its commitment to sustainable shareholder value.
More about Novartis
Novartis is a Swiss-based pharmaceutical company focused on innovative medicines. It operates primarily in the cardiovascular-renal-metabolic, immunology, neuroscience, and oncology therapeutic areas. The company prioritizes growth in key markets like the US, China, Germany, and Japan, and invests in emerging platforms such as gene & cell therapy, radioligand therapy, and xRNA.
YTD Price Performance: 7.83%
Average Trading Volume: 1,332,681
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $204.2B
Find detailed analytics on NVS stock on TipRanks’ Stock Analysis page.
